ABSTRACT

Suzetrigine is one of the revolutionary non-opioid analgesics developed with the specific intention of managing acute pain, mild to severe in intensity. As a blocker of voltage-gated sodium channels (Nav), which specifically target Nav1.7, Nav1.8, and Nav1.9, it effectively modulates the signalling pathways for pain while avoiding most of the adverse effects associated with the central nervous and the gastrointestinal systems seen in conventional analgesics and opioids. Suetrigine has a highly optimized pharmacological profile and provides advantages over existing pain management therapies, which often have risks of dependence, addiction, and adverse effects such as sedation and respiratory complications. In clinical trials involving more than 2,447 participants, suzetrigine proved to be safe and effective in reducing the intensity of pain without any risk of abuse or respiratory depression. The approval of suzetrigine by the U.S. Food and Drug Administration is a significant development in pain management strategies. By addressing the shortcomings of current analgesics, including NSAIDs, acetaminophen, and opioids, suzetrigine offers a much-needed alternative for patients suffering from acute pain conditions. In addition, its novel mechanism of action avoids the gastrointestinal and renal risks of NSAIDs but has the potential for long-term use in chronic pain management conditions such as diabetic neuropathy and postherpetic neuralgia. As healthcare systems continue to face the opioid crisis, suzetrigine represents a safer pain relief drug, addressing the critical need for effective analgesics that maintain patient safety without sacrificing efficacy. Thus, suzetrigine will play a critical role in redesigning the future of pain management. Keywords: pain, analgesia, sodium channel, Suzetrigine
Publication date: 01/07/2025

https://ijbpas.com/pdf/2025/July/MS_IJBPAS_2025_9267.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.7.9267